1st Quarter - Report

CROSSROADS STRATEGIES, LLC for MERCK & CO., INC.

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act), antimicrobial resistance, VICP Program, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act.

LobbyistCovered position, as disclosed
JASON GLEASON —
JOHN GREEN —
BRITTANY JOHNSON HERNANDEZ —
CHERYL LYNN JAEGER —
MATHEW LAPINSKI —
JASON BENJAMIN VAN PELT —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 891 (119th)

Medicare/Medicaid MMM

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

LobbyistCovered position, as disclosed
JASON GLEASON —
JOHN GREEN —
BRITTANY JOHNSON HERNANDEZ —
CHERYL LYNN JAEGER —
MATHEW LAPINSKI —
JASON BENJAMIN VAN PELT —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Taxation/Internal Revenue Code TAX

Issues related to tax reform. Inflation Reduction Act of 2022 (P.L.117-169) implementation; issues related to international taxation. Issues related to R&D tax credit.

LobbyistCovered position, as disclosed
JASON GLEASON —
JOHN GREEN —
BRITTANY JOHNSON HERNANDEZ —
CHERYL LYNN JAEGER —
MATHEW LAPINSKI —
JASON BENJAMIN VAN PELT —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

Issues related to pharmaceutical IP, supply chain, and tariffs.

LobbyistCovered position, as disclosed
JASON GLEASON —
JOHN GREEN —
BRITTANY JOHNSON HERNANDEZ —
CHERYL LYNN JAEGER —
MATHEW LAPINSKI —
JASON BENJAMIN VAN PELT —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4); H.Con.Res.14, FY2025 Budget Resolution; FY2025 Budget Reconciliation Process; all bio-pharmaceutical related provisions.

LobbyistCovered position, as disclosed
JASON GLEASON —
JOHN GREEN —
BRITTANY JOHNSON HERNANDEZ —
CHERYL LYNN JAEGER —
MATHEW LAPINSKI —
JASON BENJAMIN VAN PELT —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1968 (119th), H.Con.Res. 14 (119th)

Copyright/Patent/Trademark CPT

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

LobbyistCovered position, as disclosed
JASON GLEASON —
JOHN GREEN —
BRITTANY JOHNSON HERNANDEZ —
CHERYL LYNN JAEGER —
MATHEW LAPINSKI —
JASON BENJAMIN VAN PELT —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.